Skip to main content

Incyte Licenses Gene Patents and Databases to Agilent and Corning for Microarrays

NEW YORK, Jan 8 – In two separate agreements, Incyte has licensed its portfolio of gene patents and sequence information to both Agilent and Corning for use in their microarrays, Incyte announced Monday.

In the Corning agreement, the fiber-optics giant will have access to Incyte’s LifeSeq Gold human gene sequence database as well as Incyte’s ZooSeq animal database so it can manufacture human and animal genome microarrays. Corning’s microarray users will be able to click through on Incyte's website to Incyte’s database to buy additional genetic information as needed. Incyte will receive royalties on the sale of microarrays that Corning develops using this technology and databases.

Further financial terms of the deal were not disclosed.

“We believe this agreement will significantly enhance our ability to design and produce microarrays, and continues to strengthen our genetic content access supporting our planned full commercial microarray production in 2001,” Thomas Hinman, vice president of Corning Microarray technologies, said in a statement.

The Agilent agreement is substantially similar. Agilent has licensed Incyte’s cDNA clone sets in making animal and human gene expression microarrays. Researchers will have click-through access to Incyte’s LifeSeq gene-by-gene site so they can purchase additional information on specific genes. Incyte will also receive royalties from the sale of these arrays.

While Agilent already has custom oligonucleotide microarrays and other gene expression analysis tools on the market, Corning is a relative latecomer to the microarray market, having begun an effort in September to use its high-volume manufacturing processes to develop microarrays. In October, Corning completed a $10 million four-year agreement with MIT’s Whitehead Institute to develop the microarrays.

Incyte has entered into similar licensing agreements with two other microarray makers. It licensed its database of gene patents to Motorola, and its cDNA clones to PerkinElmer for commercialization of microarrays. In both agreements, Incyte is to receive royalties on the sale of microarrays.

 

 

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.